Full-Time

Lead - Process Design Analyst

Strategic Design & Delivery Team, Infrastructure Platform

Posted on 8/14/2025

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$100k - $225k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: London, UK

In Person

Category
Business & Strategy (2)
,
Required Skills
Agile
Product Management
Data Analysis
Requirements
  • Proven track record driving and successfully delivering complex, cross-function projects
  • Strong root-cause analysis and creative problem-solving skills, coupled with the self-motivation and leadership to drive projects to completion
  • Target Operating Model development
  • Ability to consistently produce high quality project documentation, specifically project updates, requirements and test scripts
  • Experience of working in an Agile environment, with knowledge of product management, agile prioritization and planning to enable early proof of outcomes, and how to translate long-term design ambitions into sprint-like modules using Epics, Stories or similar.
  • Technical aptitude and ability to partner with and provide sounding board to technology engineers on technical solutions
  • A disciplined organizational process, ability to work independently, and manage conflicting priorities
  • Strong written and oral communication skills with confidence and ability to communicate with senior leaders
  • Ability to deliver while working under pressure to tight deadlines; flexible and able to respond positively to changes / moving targets
  • Demonstrated success collaborating, ability to influence without authority
  • 7+ years experience
Responsibilities
  • Identifying convergence and streamlining options between similar functions within a single or across multiple business units
  • Advising business units in understanding their strategic drivers and converting these into strategic long-term objectives and business cases that provide the platform for detailed design work to start
  • Experience in using Objectives & Key Results (OKRs) or similar frameworks to help leadership define and organize their business outcomes & track that into design & planning work
  • Developing Business Process Management models to describe current state as well as target state design including Business Decision Modeling requirements
  • Working with business units to develop optimal organizational models to meet their strategic objectives
  • Working with our client excellence and regulatory teams to interpret new requirements and how they can be accommodated into their Target Operating Models
  • Leveraging analytics tools & core methods to assist with root cause analysis and identify opportunities for improvement
  • Partnering with our technology engineers & data strategists on defining architecture strategies and controls
  • Collaborating across teams to take designs into reality through design advice and the project lifecycle
  • Presenting and communicating ideas and designs
  • Facilitating and driving communication to gain input and consensus from stakeholders in multiple teams and regions
  • Staying connected to industry utilities and market vendors to help in the overall design of our strategy, processes and technology architecture and sharing this knowledge across Investment Operations
Desired Qualifications
  • Functional Architecture Design
  • Business Process Re-Engineering
  • Experience across a project lifecycle from scoping & analysis to delivery
  • Degree in Operational Strategy
  • Technical knowledge of financial service industry utilities
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE